Inducible cAMP early repressor (ICER) is an important mediator of cAMP antiproliferative activity that acts as a putative tumor suppressor gene product. In this study, we examined the regulation of ICER protein by phosphorylation and ubiquitination in human choriocarcinoma JEG-3 and mouse pituitary AtT20 cells. We found that cAMP stabilized ICER protein by inhibiting the mitogen-activated protein kinase (MAPK) cascade. Activation of the MAPK pathway increased ICER phosphorylation. ICER phosphorylation was abrogated by inhibition of the MAPK pathway either by cAMP or directly by the MAPK inhibitor PD098059. The MAPKs extracellular signal-regulated kinases 1 and 2 physically interact with ICER and mediated the phosphorylation of ICER on a critical serine residue (Ser-41). A mutant form of ICER in which Ser-41 was substituted by alanine had a half-life 4 -5 h longer than its wild-type counterpart. This alteration in stability was due to the inability of the Ser-41-mutant ICER to be efficiently ubiquitinated and degraded via the ubiquitin-proteasome pathway. These results present a novel cell signaling crosstalk mechanism at the cell nucleus between the MAPK and cAMP pathways, whereby MAPK targets a repressor of the cAMP-dependent gene expression for ubiquitination and proteasomal degradation.The MAPK 1 pathway controls cell growth by regulating gene expression, protein synthesis, nucleotide synthesis, the interaction between cyclins and cyclin-dependent kinases, and protein stability by ubiquitin-mediated proteasomal degradation (Refs. 1 and 2 and references therein). In the classic pathway, activation of MAPK occurs by peptide growth factors that bind to a transmembrane tyrosine kinase receptor. This results in the activation of the small GTP-binding protein Ras that recruits a member of the Raf kinase family (Raf-1, A-Raf, or B-Raf) to the plasma membrane. Raf phosphorylates and activates the MEKs (MEK1 and MEK2), which in turn activates the MAPKs ERK1 and ERK2 by phosphorylation on threonine and tyrosine.